[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index rising 1.3%",
    "url": "https://finnhub.io/api/news?id=343fdad991824918fdfa20f12fcbd6762a4548f8501eac2bb159b72ad02f1efd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745525158,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 134067716,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index rising 1.3%",
      "url": "https://finnhub.io/api/news?id=343fdad991824918fdfa20f12fcbd6762a4548f8501eac2bb159b72ad02f1efd"
    }
  },
  {
    "ts": null,
    "headline": "Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform",
    "summary": "Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to: Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies. Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate",
    "url": "https://finnhub.io/api/news?id=035012f8965623734f04b231b5cbb3ede04ddbca53243b0b63e58b07b9516b1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745523394,
      "headline": "Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform",
      "id": 134067717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to: Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies. Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate",
      "url": "https://finnhub.io/api/news?id=035012f8965623734f04b231b5cbb3ede04ddbca53243b0b63e58b07b9516b1b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Collaborates With Guardant Health on Oncology; Declares US$0.43 Dividend",
    "summary": "Pfizer (NYSE:PFE) recently made headlines with a strategic collaboration with Guardant Health, aimed at enhancing its oncology portfolio through advanced liquid biopsy technology. Simultaneously, the company maintained its strong commitment to shareholders by declaring a quarterly dividend. Pfizer's share price saw a modest increase of 1.59% over the past week, aligning with the broader market trend but slightly underperforming the 2.3% market surge. While these company-specific events...",
    "url": "https://finnhub.io/api/news?id=fe8fde33b5b5107863eba3893c2b7fdc72692bfc142a596a9d1b6407deb98ba3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745517389,
      "headline": "Pfizer (NYSE:PFE) Collaborates With Guardant Health on Oncology; Declares US$0.43 Dividend",
      "id": 134067718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) recently made headlines with a strategic collaboration with Guardant Health, aimed at enhancing its oncology portfolio through advanced liquid biopsy technology. Simultaneously, the company maintained its strong commitment to shareholders by declaring a quarterly dividend. Pfizer's share price saw a modest increase of 1.59% over the past week, aligning with the broader market trend but slightly underperforming the 2.3% market surge. While these company-specific events...",
      "url": "https://finnhub.io/api/news?id=fe8fde33b5b5107863eba3893c2b7fdc72692bfc142a596a9d1b6407deb98ba3"
    }
  },
  {
    "ts": null,
    "headline": "PFE vs. LLY: Which Stock Should Value Investors Buy Now?",
    "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=dd4f5bf2949376b74e18e18ab362c38551f523b57f61a788381b9b82c97e3d90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745509205,
      "headline": "PFE vs. LLY: Which Stock Should Value Investors Buy Now?",
      "id": 134067371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=dd4f5bf2949376b74e18e18ab362c38551f523b57f61a788381b9b82c97e3d90"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=ff8a0536bc458d0e4d27e9bb694fc33c367c77c1fecded6125cc1725794c5957",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745503316,
      "headline": "Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 134067374,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=ff8a0536bc458d0e4d27e9bb694fc33c367c77c1fecded6125cc1725794c5957"
    }
  },
  {
    "ts": null,
    "headline": "Are Investors Undervaluing Pfizer (PFE) Right Now?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=89a0672b998cb0287079760e6266f0f1a53d4e36bd5c3d0eb78b3efe28a7f8fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745502012,
      "headline": "Are Investors Undervaluing Pfizer (PFE) Right Now?",
      "id": 134067722,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=89a0672b998cb0287079760e6266f0f1a53d4e36bd5c3d0eb78b3efe28a7f8fc"
    }
  },
  {
    "ts": null,
    "headline": "Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics",
    "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.",
    "url": "https://finnhub.io/api/news?id=91dc7c83669546c094c8b068d0d31a5ecbe45e9bdec3d82471d875844dec028c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745500519,
      "headline": "Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics",
      "id": 134067723,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.",
      "url": "https://finnhub.io/api/news?id=91dc7c83669546c094c8b068d0d31a5ecbe45e9bdec3d82471d875844dec028c"
    }
  },
  {
    "ts": null,
    "headline": "With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns",
    "summary": "Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...",
    "url": "https://finnhub.io/api/news?id=054c1ea12032c4b0e43210b894ce9948a07ce9215bb03687ce6e68509e9de9c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745499612,
      "headline": "With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns",
      "id": 134067724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...",
      "url": "https://finnhub.io/api/news?id=054c1ea12032c4b0e43210b894ce9948a07ce9215bb03687ce6e68509e9de9c5"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth",
    "summary": "SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.",
    "url": "https://finnhub.io/api/news?id=cd267b83a21310e961245217ea9a9edcb4b74a884aae005debdf0f38f679ed21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745495940,
      "headline": "Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth",
      "id": 134062088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.",
      "url": "https://finnhub.io/api/news?id=cd267b83a21310e961245217ea9a9edcb4b74a884aae005debdf0f38f679ed21"
    }
  },
  {
    "ts": null,
    "headline": "2 No-Brainer Stocks to Buy With Less Than $30",
    "summary": "Having significant capital in the bank when investing in equities is helpful, but is by no means necessary.  If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns.  Let's consider two great options: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y).",
    "url": "https://finnhub.io/api/news?id=5547a3325bfcb2cf975de2aba0647e38b730a73a18331104e764cbe712a62816",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745491500,
      "headline": "2 No-Brainer Stocks to Buy With Less Than $30",
      "id": 134059560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Having significant capital in the bank when investing in equities is helpful, but is by no means necessary.  If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns.  Let's consider two great options: Pfizer (NYSE: PFE) and Adyen (OTC: ADYE.Y).",
      "url": "https://finnhub.io/api/news?id=5547a3325bfcb2cf975de2aba0647e38b730a73a18331104e764cbe712a62816"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
    "summary": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=0180371b60eb8a5d235b563fb943a4fdbd8aaafdfc0ee44a494acdac9950afd9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745489460,
      "headline": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
      "id": 134146413,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=0180371b60eb8a5d235b563fb943a4fdbd8aaafdfc0ee44a494acdac9950afd9"
    }
  }
]